Meeting
2018 Gastrointestinal Cancers Symposium
Regorafenib tolerance and outcomes in inner-city minority colorectal cancer population.
Authors
Ahmed Tarig Ahmed
Cook County Hospital, Chicago, IL
Ahmed Tarig Ahmed , Sindhu Janarthanam Malapati , Barbara Yim , Sunny R K Singh , Shweta Gupta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 722)
DOI
10.1200/JCO.2018.36.4_suppl.722
Abstract #
722
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).
First Author: Erwin Woff
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
First Author: Kaushal Desai
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen